Etidronate Disodium Rx
Generic Name and Formulations:
Etidronate disodium 200mg, 400mg; scored tabs.
Various generic manufacturers
Indications for Etidronate Disodium:
Treatment of symptomatic Paget's disease of bone. Prevention and treatment of heterotopic ossification after total hip replacement or due to spinal cord injury.
Swallow whole; take with a full glass of water (6–8oz) in upright position; do not lie down afterwards. Give once daily (preferred) or in divided doses at least 2hrs before or after food. Paget's: initially 5–10mg/kg/day; max 6 months (if ineffective, or if rapid bone turnover must be suppressed or to reduce elevated cardiac output: 11–20mg/kg/day; max 3 months). May retreat after 3 etidronate-free months if evidence of active disease process exists. Heterotopic ossification: hip replacement: 20mg/kg/day for 1 month before and 3 months after surgery; spinal cord injury: 20mg/kg/day for 2 weeks, then 10mg/kg/day for 10 weeks.
Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Clinically overt osteomalacia.
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Ensure adequate calcium and Vit. D intake. Risk of osteonecrosis of the jaw; consider discontinuing therapy during invasive dental procedures (eg, tooth extraction, implants, surgery). Enterocolitis. Osteomalacia and increased fracture risk in chronic use or high doses. Osteolytic lesions. Renal dysfunction: reduce dose. Pregnancy (Cat.C). Nursing mothers.
Calcium, aluminum- or magnesium-containing antacids, iron, other divalent cations reduce absorption (separate dosing by >2hrs). Monitor warfarin.
Diarrhea, nausea, musculoskeletal pain, esophagitis, esophageal ulcers/erosions, gastritis (may be severe); osteomalacia, bone fractures, jaw osteonecrosis.
Formerly known under the brand name Didronel.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness